GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acarix AB (OTCPK:ACIXF) » Definitions » Valuation Rank

ACIXF (Acarix AB) Valuation Rank


View and export this data going back to 2022. Start your Free Trial

What is Acarix AB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Acarix AB Valuation Rank Related Terms

Thank you for viewing the detailed overview of Acarix AB's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Acarix AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acarix AB (OTCPK:ACIXF) » Definitions » Valuation Rank
Comparable Companies
OSTO:NEOLA OSTO:SPEC OSTO:QLINEA OSTO:BOUL OSTO:DIGN OSTO:INTEG B OSTO:NOSA OSTO:SCIB OSTO:ARCOMA NGM:MCLR ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA ZBH
Traded in Other Exchanges
ACARIX:Sweden 7AC:Germany
Address
World Trade Center Malmo, Jungmansgatan 12, Malmo, SWE, 211 19
Website
https://www.acarix.com
Acarix AB is a Swedish medical technology company that develops innovative solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. The CADScor System uses advanced acoustics and AI technology to non-invasively rule out CAD in less than 10 minutes, with at least 96 percent certainty.